tiprankstipranks
Blurbs

Analysts Are Bullish on These Healthcare Stocks: Surface Oncology (SURF), Cytokinetics (CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Surface Oncology (SURFResearch Report), Cytokinetics (CYTKResearch Report) and AmerisourceBergen (ABCResearch Report) with bullish sentiments.

Surface Oncology (SURF)

In a report issued on August 3, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Surface Oncology, with a price target of $11.00. The company’s shares closed last Thursday at $1.80, close to its 52-week low of $1.37.

According to TipRanks.com, Kusy has 0 stars on 0-5 stars ranking scale with an average return of -40.4% and a 15.0% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Karyopharm Therapeutics, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Surface Oncology is a Strong Buy with an average price target of $11.25, representing a 525.0% upside. In a report issued on August 3, JonesTrading also maintained a Buy rating on the stock with a $12.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Cytokinetics (CYTK)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Cytokinetics yesterday and set a price target of $80.00. The company’s shares closed last Thursday at $46.72, close to its 52-week high of $49.41.

According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.1% and a 33.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $64.70 average price target, a 48.4% upside from current levels. In a report issued on August 1, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $64.00 price target.

AmerisourceBergen (ABC)

In a report issued on August 3, Eric Coldwell from Robert W. Baird reiterated a Buy rating on AmerisourceBergen, with a price target of $188.00. The company’s shares closed last Thursday at $139.27.

According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 10.1% and a 55.9% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, Cardinal Health, and IQVIA Holdings.

Currently, the analyst consensus on AmerisourceBergen is a Moderate Buy with an average price target of $171.67, a 21.5% upside from current levels. In a report issued on July 20, Argus Research also maintained a Buy rating on the stock with a $170.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SURF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More